ATORX

Alligator Bioscience

Market Cap 1,820.4M

Alligator Bioscience AB (Alligator) är ett bioteknikbolag med säte i Lund, Sverige. Bolaget grundades kring en proteinoptimeringsteknik och knoppades av 2001 från bioteknikbolaget Bioinvent International AB. Verksamheten är inriktad på att ta fram antikroppsbaserade läkemedel mot cancer och mer specifikt inriktad mot det snabbt växande fältet immunonkologi (I/O). Alligator var relativt tidigt in i I/O-området och de första stegen togs redan 2008. VD för Alligator sedan slutet av 2015 är Dr. Per Norlén. Även om han är relativt ny i rollen som vd har han en historik med bolaget och varit anställd sedan 2010, senast i rollen som medicinsk chef. Sedan han kom till bolaget har han haft en central roll i att ställa om fokus och att bygga upp kompetens inom I/O-området. Organisation består av 35 anställda specialiserad inom forskning och utveckling av proteinläkemedel, men även av flera erfarna forskare inom I/O-området. För att kunna hantera en växande projektportfölj närmaste åren räknar vi med att bolagets organisation kommer behöva stärkas ytterligare.

+ more
Today
Day High
25.50
25.2
Day Low
24.50
Day Open
25.50
Prev Close
25.50
VWAP
25.0
Volume
32K
Turnover
0.809M
Top Broker
AVA
VWAP
26.1
Avg Volume
27K
Avg Turnover
0.692M
Top Brokers
AVA/NRD
VWAP
26.6
Avg Volume
143K
Avg Turnover
3.812M
Top Brokers
CAR/AVA
VWAP
27.0
Avg Volume
93K
Avg Turnover
2.508M
Top Brokers
CAR/AVA
52 week summary
Price Range
24.5
Last
40.1
Beta
N/A
Market Cap
1,820.4M
Total Return
-33.1%
Trailing P/E
8.2
Div Yield
0.0%
Shares Outstanding
71.4M
Next Earnings Date
16 Feb
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months -10.9%
Change 12 Months -38.9%
Volume Trend
Average Volume 10 vs 60 Days -83.8%
Price VS
52 Week High -37.2%
50 Day Moving Average -10.3%
200 Day moving Average -11.8%

Add article markers

Compare Alligator Bioscience to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Per Norlén, CEO
  • Per-Olof Schrewelius, CFO
  • Executive board
  • Peter Benson, Chairman of the board
  • Carl Borrebaeck
  • Ulrika Danielsson
  • Anders Ekblom
  • Kenth Petersson
  • Jonas Sjögren
  • Laura von Schantz
Last updated: 2017-06-14 Source: Redeye
Major Owners Equity Votes
Johnson & Johnson Innovation 8.1%
8.1%
Sunstone Capital 8.1%
8.1%
Jonas Sjögren 6.8%
6.8%
Lars Spånberg 4.5%
4.5%
Investor 4.3%
4.3%
Atlas Antibodies AB 3.7%
3.7%
Stena 3.2%
3.2%
Norron Fonder 2.7%
2.7%
Investment AB Öresund 2.5%
2.5%
Catella Fonder 2.1%
2.1%
Last updated: 2017-11-16 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
+ 6,000
0 Sales
- 0
Last 24 weeks
1 Purchases
+ 6,000
0 Sales
- 0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream FI
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • 0.0%
  • -225.4%
  • 0.0%
  • -6,593.8%
  • -6,593.8%
  • -6,557.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -37.4
  • 0.0
  • 0.0
  • 0.0
  • -32.0
  • 0.5
  • 0.5
  • 0.0
  •  
  • 70.1%
  • 0.0%
  • -37
  • 31
  • 0.0
  • 2014
  •  
  •  
  • 37
  • 0
  • 0
  • 4
  • 41
  •  
  • 2
  • 0
  • 0
  • 0
  • 0
  • 54
  • 0
  • 56
  • 0
  • 98
  •  
  •  
  • 0
  • 4
  • 25
  • 29
  • 0
  • 0
  • 0
  • 29
  • 0
  • 0
  • 69
  • 0
  • 69
  • 98
  • 2014
  • 1
  • -78
  • 0
  • -77
  • 0
  • -77
  • 0
  • -77
  • 25
  • -56
  • -67
  • 2014 Q2
  • 1
  • -78
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2014 Q3
  • 1
  • -78
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2014 Q4
  • 1
  • -78
  • -77
  • 0
  • 0
  • 0
  • -77
  • 0
  • 0
  • 0
  • -77
  • 0
  • -77
  • 2015
  •  
  • 89.1%
  • 87.2%
  • 652.9%
  • 70.1%
  • 70.1%
  • 71.6%
  •  
  • 3.51
  • 3.51
  • 0.00
  •  
  • 59.0
  •  
  • -365.6
  • 0.0
  • 0.0
  • 0.0
  • -1.3
  • -1.8
  • -1.8
  • 0.0
  •  
  • 95.4%
  • 0.0%
  • -366
  • 31
  • 0.7
  • 2015
  •  
  •  
  • 366
  • 1
  • 0
  • 4
  • 370
  •  
  • 2
  • 0
  • 0
  • 0
  • 0
  • 43
  • 0
  • 46
  • 0
  • 416
  •  
  •  
  • 0
  • 5
  • 14
  • 19
  • 0
  • 0
  • 0
  • 19
  • 0
  • 0
  • 397
  • 0
  • 397
  • 416
  • 2015
  • 290
  • -87
  • 0
  • 203
  • 0
  • 203
  • 0
  • 203
  • -11
  • 11
  • 201
  • 2015 Q1
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 290
  • -87
  • 203
  • 0
  • 0
  • 0
  • 203
  • 0
  • 4
  • 0
  • 207
  • 0
  • 207
  • 2016 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2016 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2016 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2016 Q1
  • 43
  • -19
  • 25
  • -1
  • 0
  • 0
  • 24
  • 0
  • -0
  • 0
  • 24
  • 0
  • 24
  • 2016 Q2
  • 4
  • -29
  • -25
  • -23
  • 0
  • 0
  • -48
  • 0
  • 3
  • 0
  • -45
  • 0
  • -45
  • 2016 Q3
  • 5
  • -13
  • -8
  • -1
  • 0
  • 0
  • -9
  • 0
  • 2
  • 0
  • -8
  • 0
  • -8
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-05-29 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.


Community Posts

Be the first to write something about this company in the community.

Create new post